The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta

Turkish Journal of Pediatrics

Volumn 46, Issue 4, 2004, Pages 322-328

  Adiyaman, Pelin ^a   Öcal, Gönül ^a   Berberoǧlu, Merih ^a   Evliyaoǧlu, Olcay ^a   Aycan, Zehra ^a   Çetinkaya, Ergun ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Clinical and radiological improvement; Intravenous pamidronate; Osteogenesis imperfecta

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PAMIDRONIC ACID; PARACETAMOL;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BONE DENSITY; BONE DISEASE; BONE MINERALIZATION; BONE PAIN; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DENSITOMETRY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; GROWTH RATE; HUMAN; HYPERCALCIURIA; HYPOCALCEMIA; INDEPENDENCE; LUMBAR SPINE; MALE; MEASUREMENT; METABOLIC DISORDER; MOBILIZATION; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PROSPECTIVE STUDY; PUBERTY; QUESTIONNAIRE; RISK REDUCTION; SCORING SYSTEM; SPINE RADIOGRAPHY; UREA NITROGEN BLOOD LEVEL; VERTEBRA BODY; VERTEBRA MALFORMATION; VOLUMETRY; WRIST RADIOGRAPHY;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; BONE AND BONES; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; OSTEOGENESIS IMPERFECTA; PILOT PROJECTS; PROSPECTIVE STUDIES; SPINE; TREATMENT OUTCOME;

EID: 11344251281     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 1999; 21: 1025-1044.
2. Papapoulos SE. Biphosphonates in the treatment of osteoporosis. Ann Med Interne (Paris) 2000; 151: 504-510.
3. Body JJ, Barl R, Burchardt P, et al. International Bone Cancer Study Group. Current use of biphosphonates in oncology. J Clin Oncol 1998; 16: 3890-3899.
4. Glorieux FH. Biphosphonate therapy for severe osteogenesis imperfecta. J Pediatr Endocrinol Metab 2000; 13: 989-992.
5. Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta-lack of correlation between clinical severity, age onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002; 15: 163-174.
6. Roux C, Dougados M. Treatment of patients with Paget's disease of bone. Drugs 1999; 58: 823-830.
7. Papapoulos SE. Paget's disease of bone: clinical, pathogenetic and therapeutic aspects. Ballieres Clin Endocrinol Metab 1997; 11: 117-143.
8. Zacharin M, O'Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 2000; 137: 403-409.
9. Zacharin M, Cundy T. Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous biphosphonates. J Pediatr 2000; 137: 410-415.
10. Cremers S, Sparidans R, den Hartigh J, et al. A pharmacokinetic and pharmacodynamic model for intravenous biphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002; 57: 883-890.
11. Gonzales E, Pavia C, Ros J, et al. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001; 14: 529-533.
12. Bembi B, Pharma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997; 131: 622-625.
13. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952.
14. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001; 160: 641-644.
15. Aström E, Söderhall S. Beneficial effect of biphosphonate during five years. J Pediatr Endocrinol Metab 2001; 14: 529-533.
16. Fleisch H. Biphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
17. Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthnop 1981; 158: 111-122.
18. Kröger H, Kotaniemi A, Vainio P, Alhava E. Bone densitometry of the spine and femur in children by dual-energy X-ray absorptiometry. Bone Miner 1992; 17: 75-85.
19. Lu PW, Cowell CT, Lloyd-Jones SA, Briody JN, Howman-Giles R. Volumetric bone mineral density in normal subjects, aged 5-27 years. J Clin Endocrinol Metab 1996; 81: 1586-1590.
20. Peel Eastell R. Diagnostic value of estimated volumetric bone mineral density of the lumbar spine in osteoporosis. J Bone Miner Res 1994; 7: 317-320.
21. Meerten Elv P, Kroon HM, Papapoulos SE. Epi-and metaphyseal changes in children caused by administration of biphosphonates. Radiology 1992; 184: 249-254.
22. Lin HJ. Biphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
23. Giraud F, Meunier PJ. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients. Joint Bone Spine 2002; 69: 486-490.